Scientific publications

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming

Oct 15, 2016 | Magazine: Cancer Research

María E Rodriguez-Ruiz  1 , Inmaculada Rodriguez  2 , Saray Garasa  2 , Benigno Barbes  2 , Jose Luis Solorzano  3 , Jose Luis Perez-Gracia  3 , Sara Labiano  2 , Miguel F Sanmamed  4 , Arantza Azpilikueta  2 , Elixabet Bolaños  2 , Alfonso R Sanchez-Paulete  2 , M Angela Aznar  2 , Ana Rouzaut  2 , Kurt A Schalper  5 , Maria Jure-Kunkel  6 , Ignacio Melero  7


Preclinical and clinical evidence indicate that the proimmune effects of radiotherapy can be synergistically augmented with immunostimulatory mAbs to act both on irradiated tumor lesions and on distant, nonirradiated tumor sites.

The combination of radiotherapy with immunostimulatory anti-PD1 and anti-CD137 mAbs was conducive to favorable effects on distant nonirradiated tumor lesions as observed in transplanted MC38 (colorectal cancer), B16OVA (melanoma), and 4T1 (breast cancer) models. The therapeutic activity was crucially performed by CD8 T cells, as found in selective depletion experiments.

Moreover, the integrities of BATF-3-dependent dendritic cells specialized in crosspresentation/crosspriming of antigens to CD8+ T cells and of the type I IFN system were absolute requirements for the antitumor effects to occur. The irradiation regimen induced immune infiltrate changes in the irradiated and nonirradiated lesions featured by reductions in the total content of effector T cells, Tregs, and myeloid-derived suppressor cells, while effector T cells expressed more intracellular IFNγ in both the irradiated and contralateral tumors.

Importantly, 48 hours after irradiation, CD8+ TILs showed brighter expression of CD137 and PD1, thereby displaying more target molecules for the corresponding mAbs. Likewise, PD1 and CD137 were induced on tumor-infiltrating lymphocytes from surgically excised human carcinomas that were irradiated ex vivo

These mechanisms involving crosspriming and CD8 T cells advocate clinical development of immunotherapy combinations with anti-PD1 plus anti-CD137 mAbs that can be synergistically accompanied by radiotherapy strategies, even if the disease is left outside the field of irradiation.

CITA DEL ARTÍCULO  Cancer Res. 2016 Oct 15;76(20):5994-6005.  doi: 10.1158/0008-5472.CAN-16-0549. Epub 2016 Aug 22.